Double-blind, placebo-controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: anabolic effect and functional improvement.

Johannsson G, Bengtsson BA, Ahlmén J

American journal of kidney diseases : the official journal of the National Kidney Foundation1 Apr 1999Cited by 59 (Europe PMC)

PMID10196013DOI10.1016/s0272-6386(99)70223-4PepBankPUB-10196013

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In elderly hemodialysis patients, GH increased serum IGF-I compared with placebo.
In plain wordsIn elderly hemodialysis patients, GH increased IGF-I more than placebo.
Peptide
HGH (somatotropin)
Outcome
IncreaseIGF-I
Study
n = 20
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
66.7 microgram/kg three times weekly · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
GH treatment increased the serum concentration of insulin-like growth factor-I (IGF-I), IGF-I/IGF-binding protein-3 ratio, fat-free mass, and the serum concentration of albumin compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty hemodialysis patients with a mean age of 71.7 years (range, 53 to 92 years) were included on a 6-month, randomized, double-blind, placebo-controlled trial of GH treatment.
Summary · context
The dose of GH was 66.7 microgram/kg, administered subcutaneously three times weekly immediately after each dialysis session.
Report a problemFND-1019601301
02HumanRandomized controlled trialEfficacy outcome
In elderly hemodialysis patients, GH increased the IGF-I/IGFBP-3 ratio compared with placebo.
In plain wordsIn elderly hemodialysis patients, GH increased the IGF-I/IGFBP-3 ratio more than placebo.
Peptide
HGH (somatotropin)
Outcome
IncreaseIGF-I/IGFBP-3 ratio
Study
n = 20
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
66.7 microgram/kg three times weekly · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
GH treatment increased the serum concentration of insulin-like growth factor-I (IGF-I), IGF-I/IGF-binding protein-3 ratio, fat-free mass, and the serum concentration of albumin compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty hemodialysis patients with a mean age of 71.7 years (range, 53 to 92 years) were included on a 6-month, randomized, double-blind, placebo-controlled trial of GH treatment.
Summary · context
The dose of GH was 66.7 microgram/kg, administered subcutaneously three times weekly immediately after each dialysis session.
Report a problemFND-1019601302
03HumanRandomized controlled trialEfficacy outcome
In elderly hemodialysis patients, GH increased fat-free mass compared with placebo.
In plain wordsIn elderly hemodialysis patients, GH increased fat-free mass more than placebo.
Peptide
HGH (somatotropin)
Outcome
IncreaseFat-free mass
Study
n = 20
Comparator
Placebo
Outcome group
Body composition · Metabolic and weight
Studied dose
66.7 microgram/kg three times weekly · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
GH treatment increased the serum concentration of insulin-like growth factor-I (IGF-I), IGF-I/IGF-binding protein-3 ratio, fat-free mass, and the serum concentration of albumin compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty hemodialysis patients with a mean age of 71.7 years (range, 53 to 92 years) were included on a 6-month, randomized, double-blind, placebo-controlled trial of GH treatment.
Summary · context
The dose of GH was 66.7 microgram/kg, administered subcutaneously three times weekly immediately after each dialysis session.
Report a problemFND-1019601303
04HumanRandomized controlled trialEfficacy outcome
In elderly hemodialysis patients, GH increased serum albumin compared with placebo.
In plain wordsIn elderly hemodialysis patients, GH increased serum albumin more than placebo.
Peptide
HGH (somatotropin)
Outcome
IncreaseSerum albumin
Study
n = 20
Comparator
Placebo
Outcome group
Body composition · Whole body
Studied dose
66.7 microgram/kg three times weekly · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
GH treatment increased the serum concentration of insulin-like growth factor-I (IGF-I), IGF-I/IGF-binding protein-3 ratio, fat-free mass, and the serum concentration of albumin compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty hemodialysis patients with a mean age of 71.7 years (range, 53 to 92 years) were included on a 6-month, randomized, double-blind, placebo-controlled trial of GH treatment.
Summary · context
The dose of GH was 66.7 microgram/kg, administered subcutaneously three times weekly immediately after each dialysis session.
Report a problemFND-1019601304
05HumanRandomized controlled trialEfficacy outcome
In elderly hemodialysis patients, GH increased handgrip strength compared with placebo.
In plain wordsIn elderly hemodialysis patients, GH increased handgrip strength more than placebo.
Peptide
HGH (somatotropin)
Outcome
IncreaseHandgrip strength
Study
n = 20
Comparator
Placebo
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
66.7 microgram/kg three times weekly · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Handgrip strength increased in response to GH treatment compared with placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty hemodialysis patients with a mean age of 71.7 years (range, 53 to 92 years) were included on a 6-month, randomized, double-blind, placebo-controlled trial of GH treatment.
Summary · context
The dose of GH was 66.7 microgram/kg, administered subcutaneously three times weekly immediately after each dialysis session.
Report a problemFND-1019601306
06HumanNon-randomized trialEfficacy outcome
In elderly hemodialysis patients receiving GH, the number with serum albumin below 40 g/L fell by a factor of three.
In plain wordsIn elderly hemodialysis patients receiving GH, the number with low albumin fell by a factor of three.
Peptide
HGH (somatotropin)
Outcome
DecreaseLow albumin prevalence
Study
n: not reported in source
Outcome group
Body composition · Whole body
Studied dose
66.7 microgram/kg three times weekly · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Reduction in number of patients with serum albumin below 40 g/L
3 fold (factor)
GH-treated group
Source sentences
Summary
The number of patients with serum albumin levels less than 40 g/L was reduced by a factor of three in the GH-treated group.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty hemodialysis patients with a mean age of 71.7 years (range, 53 to 92 years) were included on a 6-month, randomized, double-blind, placebo-controlled trial of GH treatment.
Summary · context
The dose of GH was 66.7 microgram/kg, administered subcutaneously three times weekly immediately after each dialysis session.
Report a problemFND-1019601305

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.